Linked Life Data

7022295

Source:http://linkedlifedata.com/resource/pubmed/id/7022295

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1981-10-14
pubmed:abstractText
104 nonrandomized patients suffering from metastatic breast cancer were treated with monthly cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). One group (group A, 44 patients) received low-dose CMF and another one (group B, 60 patients) received standard doses. In both cases, therapy was cycled every 29 days. Group A patients had a response rate of 50.7%, including 5 complete remissions. The median duration of response was 8.2 months. For group B patients, the response rate was of 68.1%, including 10 complete remissions. The median duration of response was 10.6 months. Toxicity was greater in group B patients, the main side effects being nausea, vomiting, leukopenia, thrombocytopenia, alopecia and stomatitis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0030-2414
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
257-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial